Caxton Associates (New York)’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Caxton Associates (New York)’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-75,000	Closed	-$679K	–	310
2013 Q4	$679K	Buy	+75,000	New	+$542K	0.02%	181

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Caxton Associates (New York)'s CADX Position: Q1 2014 in Review

Caxton Associates (New York) sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 75,000 shares — an estimated $679K sold.

Caxton Associates (New York) first reported a position in CADX in Q4 2013 and held it in 1 quarter. The position peaked at $679K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

Caxton Associates (New York) reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
Caxton Associates (New York) sold 75,000 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $679K.
Caxton Associates (New York) first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q4 2013 and held it in 1 quarter.
Caxton Associates (New York)'s CADENCE PHARMACEUTICALS, INC COM STK position peaked at $679K in Q4 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Caxton Associates (New York)'s 13F filing for Q1 2014, filed 15 May 2014.